Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL I V versus FLAGYL I V RTU IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL I V versus FLAGYL I V RTU IN PLASTIC CONTAINER.
FLAGYL I.V. vs FLAGYL I.V. RTU IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
None Documented
None Documented
8 hours (range 6-12 hours) in adults; prolonged in hepatic impairment (up to 20 hours) and neonates.
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
Renal (60-80% unchanged), fecal (6-15% as metabolites), biliary (minor).
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
Category C
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic